Structure-Activity Relationship of Novel Lactam Based Histone Deacetylase Inhibitors as Potential Anticancer Drugs

  • Yang, Jee-Sun ;
  • Chun, Tae-Gyu ;
  • Nam, Ky-Youb ;
  • Kim, Hwan-Mook ;
  • Han, Gyoon-Hee
  • Received : 2011.09.26
  • Accepted : 2012.03.12
  • Published : 2012.06.20



Histone deacetylase (HDAC);Quantitative structure-activity relationship (QSAR);Lactam based histone deacetylase inhibitor


  1. Cosio, B. G.; Mann, B.; Ito, K.; Jazrawi, E.; Barnes, P. J.; Chung, K. F.; Adcock, I. M. Am. J. Respir. Crit. Care Med. 2004, 170(2), 141.
  2. Kouzarides, T. Curr. Opin. Genet. Dev. 1999, 9(1), 40.
  3. Mai, A.; Massa, S.; Pezzi, R.; Rotili, D.; Loidl, P.; Brosch, G. J. Med. Chem. 2003, 46(23), 4826.
  4. Halkidou, K.; Gaughan, L.; Cook, S.; Leung, H. Y.; Neal, D. E.; Robson, C. N. Prostate. 2004, 59(2), 177.
  5. Osada, H.; Tatematsu, Y.; Saito, H.; Yatabe, Y.; Mitsudomi, T.; Takahashi, T. Int. J. Cancer 2004, 112(1), 26.
  6. Marks, P. A. Oncogene 2007, 26(9), 1351.
  7. Paris, M.; Porcelloni, M.; Binaschi, M.; Fattori, D. J. Med. Chem. 2008, 51(6), 1505.
  8. Furumai, R.; Matsuyama, A.; Kobashi, N.; Lee, K. H.; Nishiyama, M.; Nakajima, H.; Tanaka, A.; Komatsu, Y.; Nishino, N.; Yoshida, M.; Horinouchi, S. Cancer Res. 2002, 62(17), 4916.
  9. Beckers, T.; Burkhardt, C.; Wieland, H.; Gimmnich, P.; Ciossek, T.; Maier, T.; Sanders, K. Int. J. Cancer 2007, 121(5), 1138.
  10. The Huntington Study Group. Neurology 2001, 57(3), 397.
  11. Leoni, F.; Fossati, G.; Lewis, E. C.; Lee, J. K.; Porro, G.; Pagani, P.; Modena, D.; Moras, M. L.; Pozzi, P.; Reznikov, L. L.; Siegmund, B.; Fantuzzi, G.; Dinarello, C. A.; Mascagni, P. Mol. Med. 2005, 11(1-12), 1.
  12. Kim, H. M.; Hong, S. H.; Kim, M. S.; Lee, C. W.; Kang, J. S.; Lee, K.; Park, S. K.; Han, J. W.; Lee, H. Y.; Choi, Y.; Kwon, H. J.; Han, G. Bioorg. Med. Chem. Lett. 2007, 17(22), 6234.
  13. Kim, H. M.; Lee, K.; Park, B. W.; Ryu, D. K.; Kim, K.; Lee, C. W.; Park, S. K.; Han, J. W.; Lee, H. Y.; Han, G. Bioorg. Med. Chem. Lett. 2006, 16(15), 4068.
  14. Kim, H. M.; Ryu, D. K.; Choi, Y.; Park, B. W.; Lee, K.; Han, S. B.; Lee, C. W.; Kang, M. R.; Kang, J. S.; Boovanahalli, S. K.; Park, S. K.; Han, J. W.; Chun, T. G.; Lee, H. Y.; Nam, K. Y.; Choi, E. H.; Han, G. J. Med. Chem. 2007, 50(11), 2737.
  15. Hagler, A. T.; Lifson, S.; Dauber, P. J. Am. Chem. Soc. 1979, 101(18), 5122.
  16. Finnin, M. S.; Donigian, J. R.; Cohen, A.; Richon, V. M.; Rifkind, R. A.; Marks, P. A.; Breslow, R.; Pavletich, N. P. Nature 1999, 401(6749), 188.
  17. Stote, R. H.; Karplus, M. Proteins 1995, 23(1), 12.
  18. Liu, X.; Tu, M.; Kelly, R. S.; Chen, C.; Smith, B. J. Drug Metabolism and Disposition 2004, 32(1), 132.

Cited by

  1. Property-Based Optimization of Hydroxamate-Based γ-Lactam HDAC Inhibitors to Improve Their Metabolic Stability and Pharmacokinetic Profiles vol.55, pp.23, 2012,
  2. Discovery of Pyridone-Based Histone Deacetylase Inhibitors: Approaches for Metabolic Stability vol.8, pp.2, 2013,
  3. Lactam-Based HDAC Inhibitors for Anticancer Chemotherapy: Restoration of RUNX3 by Posttranslational Modification and Epigenetic Control vol.9, pp.3, 2013,
  4. Histone Deacetylase Inhibitors in Clinical Studies as Templates for New Anticancer Agents vol.20, pp.3, 2015,
  5. Design and Validation of FRESH, a Drug Discovery Paradigm Resting on Robust Chemical Synthesis vol.6, pp.5, 2015,
  6. Quantitative structure–activity relationship analysis and virtual screening studies for identifying HDAC2 inhibitors from known HDAC bioactive chemical libraries vol.28, pp.3, 2017,